Biblio
Absence of terminal deoxynucleotidyl transferase expression in T-ALL/LBL accumulates chromosomal abnormalities to induce drug resistance. Int J Cancer. 2023.
Correction: Targeting ARHGEF12 promotes neuroblastoma differentiation, MYCN degradation, and reduces tumorigenicity. Cell Oncol (Dordr). 2023.
Deciphering the placental abnormalities associated with somatic cell nuclear transfer at single-nucleus resolution. Protein Cell. 2023.
The driving mechanism and targeting value of mimicry between vascular endothelial cells and tumor cells in tumor progression. Biomed Pharmacother. 2023;165:115029.
. Extracellular Vesicles and Ischemic Cardiovascular Diseases. Adv Exp Med Biol. 2023;1418:57-68.
. . Targeting ARHGEF12 promotes neuroblastoma differentiation, MYCN degradation, and reduces tumorigenicity. Cell Oncol (Dordr). 2022.
Targeting miR-30d reverses pathological cardiac hypertrophy. EBioMedicine. 2022;81:104108.
Modeling leukemia with pediatric acute leukemia patient-derived iPSCs. Stem Cell Res. 2021;54:102404.